July 1, 2025 • 33 mins
Louise Jopling is the Chief Scientific and Innovation Officer at the Babraham Research Campus and Entrepreneur-in-Residence at the Babraham Institute.
Sarah and Louise talk about
- Her career journey from immunology research to business leader and mentor
- Why hearing about the real-world impact of health innovations still gives her goosebumps
- The Babraham Research Campus ‘melting pot’ which creates a unique environment for research commercialisation and collaboration
Find out more
- Read the show notes and transcript on the podcast website
- Connect to Louise on LinkedIn
- Find out about the Babraham Research Campus and Babraham Institute
About Research Adjacent
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Louise Jopling (00:01):
Now you can make your career sound as, oh, it was
all planned out when I was 15and this is the path I went on.
We know that's all gonnabe generally hogwash.
The impact that you knew about oryou could see for the patients, the
quality of life and that permeating notjust for that patient, but for their
(00:22):
family members or their social lives.
I still get goosebumps now justeven talking to you about it.
It's such a hard and lonely journey forthe founders and for those small companies
I'm just blown away by their resilience.
Sarah McLusky (00:41):
Hello there.
I'm Sarah McLusky andthis is Research Adjacent.
Each episode I talk to amazing researchadjacent professionals about what
they do and why it makes a difference.
Keep listening to find out why wethink the research adjacent space
is where the real magic happens.
(01:05):
Hello and welcome to theResearch Adjacent podcast.
I'm your host, Sarah McLusky, andtoday we'll be meeting Louise Jopling.
Louise is currently the ChiefScientific and Innovation Officer
at the Babraham Research Campus, abiotech business park in Cambridge.
She's also entrepreneur in residenceat the academic Babraham Institute,
which is on the same site.
Louise originally aspired to be a vet,but became an immunologist instead.
(01:29):
She started out on an academic researchpath, but ultimately moved into the
commercial side of the biotech industry,a career move which included launching the
psoriasis drug Stelara and commercialisingother healthcare innovations.
Now she supports both fledging andestablished businesses, as well as
helping academic researchers explore thepotential applications of their work.
(01:49):
In our conversation, we talk about whythe Babraham Research Campus is such a
special place, her career story and whymaking a difference to real people is
what gets her out of bed in the morning.
Listen on to hear Lou's story.
Welcome Lou along to theResearch Adjacent podcast.
It's fantastic to have you here.
(02:10):
I wonder if we could begin byjust hearing a little bit about
who you are and what you do.
Louise Jopling (02:16):
Great.
Thanks Sarah, and lovely to meet you.
So yes, Louise Jopling.
My day job is as Chief Scientific andInnovation Officer at the Babraham
Research Campus in Cambridge.
I'm also a Royal Society entrepreneurin residence at the Babraham Institute.
My day job as CSIO is very much aroundworking with the 60 life sciences
(02:45):
companies that we have on campus, andthey are anything from a two person
startup through to a hundred, 150person grow on scale up company that
have grown while speaking on campus,perhaps over the past decade or more.
And it's understandingwhat their needs are.
Helping, especially the small companiescome out of stealth mode, develop
(03:07):
their data package so that they becomeready to put in front of investors.
Making those connectionsbetween researchers, clinical
teams as well and investors.
Investors in particular because ofthe financial markets that we're
in, particularly in life sciences.
Sarah McLusky (03:26):
So yeah, at the Babraham Research campus, then
it's a site so near Cambridge.
Louise Jopling (03:31):
Yes, that's right.
Yeah.
About six miles south of Cambridge.
So yeah, we are in, inthe southern cluster.
If you know where AddenbrookesHospital is and if you know where
the Wellcome Genome Campus is, thenwe're right slap bang in the middle.
Okay.
Yeah.
You're driving past us,so pop in and say hi.
Sarah McLusky (03:48):
Yeah.
And so it's all focused on lifesciences then all the research
that goes on on that site.
Could you give us maybe a coupleof examples of the sorts of things
that people are doing there?
Louise Jopling (03:59):
Oh yeah.
So we've got companies that aresupporting other companies in their
development, their drug discovery andtheir drug development capabilities.
So often small companies don'thave those skill sets in-house.
Maybe haven't got quite theindustry training in generating
(04:22):
those robust data packages.
So not quite acting as a CRO, but orcontract research organisation, but
actually working in true partnership toenable them to develop that data package
for toxicology, for their formulationof their drug or their molecule.
So that's a sort of very high levelexample for one of the companies.
(04:45):
And then we've got some very early earlystage startup companies, very much around
antibody and biologics engineering.
Sarah McLusky (04:54):
Yeah.
Louise Jopling (04:55):
So as a campus, monoclonal antibodies are our sweet spot these days.
Quite a lot of those proteinmodalities are very much around
the antibody drug conjugates.
It's a lot about AI or machinelearning, helping inform the best
target to go after or targets.
And the best combinations, let'ssay, of whether it's two, two drugs
(05:18):
in combination or whether it's aparticular conjugate once that molecule
has gotten onto or inside the cell.
Yeah, the, and the research focusof the Institute is very much around
we, if we say healthy aging, thatsort of makes us tend to think about
the later stages of the life course.
But actually the research focusesacross all life stages for human health.
(05:42):
So from birth to death.
And it's really about we allknow we are living longer, but
we're not healthier for longer.
Yeah.
We all still have an average of aboutthe last 20 years is in poor health,
and that's where the health healthcareorganisation really is needed.
So it's aiming for thatlifespan to be extended.
Sarah McLusky (06:04):
Oh, fantastic.
And I imagine having all of thosecompanies and that intense research
all happening in the same placeis fantastic for support and
collaboration and those sorts of things.
And it, it sounds like that'svery much part of your role.
Louise Jopling (06:17):
Absolutely.
Yeah.
We've got the academic researchersand the companies on campus,
companies off campus as well.
Theoretically on, even within theperimeter of our campus, and we
are on 430 acres, I should say.
We don't use that by any stretch.
And, again, you could imagine justeven getting between buildings, but,
(06:40):
just to have that close proximity.
And we've got a central sort ofbuilding where people from all
across the campus come for theirlunch, their coffees, their meetings.
So it creates, I call it the meltingpot 'cause that's really where
those serendipitous interactionscould and should be happening.
Mm-hmm.
And part of what I want to bring aswell is how can we really maximize that?
(07:03):
So you're not always,you need a critical mass.
You need to be coming to where everybodyis, but can we enable that at other parts
of the campus as well and in other ways?
Yeah.
But I think through the funding that,that we get through the BBSRC, which
is the Biotechnology and BiologicalSciences Research Council that
(07:25):
really does it pump primes thoseacademic industry partnerships.
And there's also a collaborative PhDstudentship programmme on campus that
has supported or is supporting 22 PhDstudents all at different stages of their
journey where they have to spend at leastthree months in their industrial company.
(07:50):
Oh yeah.
organisation.
Now, whether that's three months asa single time period, or whether it's
a week here, a week there, but theyget that industry supervisor as well.
So Really, yeah.
Really great opportunities.
Sarah McLusky (08:04):
Really fantastic.
Yes.
To connect up that research withthat real world potential impact.
Yeah.
Which is such a big aim now for research.
So how does all of this dovetailwith the entrepreneur in residence
role that you have as well?
Louise Jopling (08:19):
Yeah, I'd say dovetails seamlessly.
Yeah.
But obviously I would say that.
So the entrepreneur in residencerole, so that is specifically
for the academic Institute.
And it is to support the translationand centres of the research
conducted within the Institute.
(08:39):
Now it's a smallinstitute about 350 staff.
So you know, mostly scientists from PhDstudent up through to group leaders.
But there's also someheads of core facilities.
So these are real capability centresof excellence, if you like that
(09:00):
are funded by BBSRC, particularlyto serve the academic research.
But where bandwidth exists withinthose core facilities and what
I mean by those core facilities,it might be a flow cytometry.
It might be cell it might be sequencing,might be an animal unit as well 'cause
often some analysis needs to be conductedin in vivo. So they're just some examples.
(09:27):
But where there's bandwidth withinthose facilities, then the companies
themselves that are on campus canactually pay to to use those services
and to enable their discoveries and onevery small company, they're in stealth
currently, so I can't say their name.
Yeah.
But did describe being on campus ashaving your own CRO contract research
(09:51):
organisation on your doorstep.
So he, the CEO and founder wasparticularly, he was walking over
to our central stores facility.
Doesn't sound very exciting, butactually it's this massive procurement
hub, off the scale, that enables thescience for the companies and for
(10:15):
the institute to happen seamlessly.
They're not have, the small company isnot having to negotiate with 500 different
suppliers for basic things like glovesthrough to high, highly complex stuff.
They can just move in, move onto campus, crack on with their
science and everything else is.
(10:35):
Is, taken care of.
But going back to the institute itself,obviously it conducts many more enabling
services in addition to the research,but yeah, the world leading research,
high impact papers from the groupleaders, the PhD students, and everybody
(10:57):
in between, and all enabled by thatinfrastructure and the capabilities.
So yeah, it, as I say, it's asmall institute relative to, quite
large universities, et cetera.
But that's meant I've been reallyable to get under the bonnet of all
of the science that's going on hereand all of those centres projects.
(11:19):
And I think one of my biggest challengesor things that I wrestled with at
the start of the fellowship was howcan I make an impact one day a week?
Parachuting into the institute andand it was really getting under the
bonnet of all of the programmmesthat were in the commercialisation
(11:39):
portfolio, let's call it, and workingout, these are the ones that are
perhaps more, more mature or that,that really, I could bring an impact.
So there's about four or five that I'mreally actively working on it doesn't
mean I'm ignoring the others, but it just,they're not all equal at the same moment.
Sarah McLusky (11:59):
Yeah.
And also as you say, one day a week, youcan only do a limited amount of stuff.
So you have to prioritizeto a certain extent.
Yeah.
Louise Jopling (12:09):
I think, yeah, I think it's like when you start any
new job you think of your, what'syour 30, 60, 90 day plan or the
first a hundred days gonna look like.
And I very quickly realized,actually my first 30 days is
really only going to be four days.
So that was a real awakening.
And, not a bad thing, but it just, meansthat, yeah, you do focus and prioritize,
(12:32):
but I think the other piece that.
It's not just about the science andtranslating that is a core piece, but it
is also about and this is the nature ofthis podcast, research adjacent, and it
is about helping hone and inspire sortof the scientists from wherever they
(12:55):
are in their career journey, in theirown research and their own aspirations.
And I got to present a Science360 talk, which was very much
talk us through your career.
Now you can make your career soundas, oh, it was all planned out when I
was 15 and this is the path I went on.
(13:15):
We know that's all gonnabe generally hogwash.
Sarah McLusky (13:18):
Yeah.
Louise Jopling (13:18):
For, majority of us.
And just talking that through andactually bringing that to life.
And it wasn't just attended bythe more junior or people at the
earlier stages of their career.
There were some really quite seniorindividuals in that audience asking
particular questions pertinent to their,where they were at that moment in time,
(13:41):
whether that was from a professional,but also from a personal perspective.
And a lot of it is howdoes one manage one's time.
None of, I think if anybody hadgot that nailed, we'd have patented
it and be making yeah, money out.
Sarah McLusky (13:55):
Yeah somebody would be making a lot of money out it,
Louise Jopling (13:57):
B ut I think sometimes one can project things as if, yeah,
it's all sorted and it's all a doddleand that's how it can look to others.
But actually really getting underthe skin of either what drives me or
what, where you might have had to makepersonal sacrifices or compromises.
(14:18):
Yeah.
It's, it just shows that authenticityand the fact that you're human.
Sarah McLusky (14:23):
Yeah.
And I think that's leading us reallynicely then to just invite you to tell
us a bit about your career journey,about how you've ended up where you are
now, what kind of jobs you've done alongthe way what, what's your path been?
Louise Jopling (14:37):
Yeah.
So overall so I'm a scientist by training.
I always wanted to be a vet. So fromwhen I was about 11, when unfortunately
my cat needed to be put down.
I, he was my cat and I felt if Iwas the vet, I'd have saved him.
Of course what an arrogant 11-year-old,of course you're gonna think that.
(14:57):
However, followed that and focusedup purely on science throughout
GCSEs A levels and university.
I didn't get into veterinary atthe time, but I'd got my my other
courses I'd applied for animalbiology, so zoology, but I wanted
to specialise in parasitology.
So worms, parasites.
(15:19):
Yeah.
Which led me to studyup in Scotland actually.
And it was based on where the course was.
I was always fascinated by howparasites evade the host immune system.
Sarah McLusky (15:30):
Yeah.
Louise Jopling (15:30):
Again, that then led me onto my immunology research path.
So I describe, I'm nolonger a parasitologist.
I still remember all of those things.
But as a, as an immunologist, Igot a very great grounding in my
first two roles after I graduated.
And I should just say after I graduatedfrom the University of Aberdeen, I
(15:55):
did an eight week summer studentshipactually at the Babraham Institute.
And I didn't realize quite howcircular this was all going to be.
So again, I could make that be a perfectstory, but it's not meant that way anyway.
I did a couple of research assistantposts to get experience in the lab.
One of which, at the University ofEdinburgh at the Center for HIV research.
(16:19):
And at that time, so that was the midnineties when chemokine receptors,
these G protein coupled receptorshad been identified as co-receptors
for viral entry into cells.
They were facilitating the HIV virus,getting into cells and then amplifying.
And that was a really sweettime in as much as it really
(16:43):
captured my scientific interest.
And it was, we were on the startof that crest of the wave around
that particular area of research.
And so really I followed that familyof receptors throughout probably
the next decade plus of my career.
And that was in bothacademia but also in biotech.
(17:04):
So I did my two research assistantposts, got experience in the lab,
competent, and I then applied to what wasEurope's leading chemokine receptor lab.
And just the letter I wrote I read itback some years ago and it was quite
cringe, but my timing was fantastic.
(17:25):
It was all I one, the chemokine receptorswere wonderful, this, that, and the other.
My research and that I, butI really wanted to do PhD.
Fortunately that lab at the timebased at Imperial College had a,
had attracted some industry funding.
So in essence I was industry funded.
It was a US biotech company.
And so for three years I conductedmy PhD research and I think what
(17:48):
was great was I was able to conductthat research within three years.
So from registration to submission,
Sarah McLusky (17:55):
That is impressive.
Louise Jopling (17:57):
Yeah, no, thank you.
But I think it was because I'dalready earned my stripes and got
my lab skills in the two years priorin those research assistant posts.
So again, that, that really enabled that.
Anyway, I then followed the receptorI'd been working on in my PhD out
to Boston to Harvard Med School.
So I was working at Children'sHospital and that was fantastic.
(18:19):
So then in 2000, end of2002, I came back to the UK.
I always thought I was gonnastay in academia to be quite
honest, but never say never.
And I came back to a job in biotech.
Yeah.
And at the time it was Britain'sbiggest biotech company called Celltech.
And Celltech had a small moleculesite in Cambridge on Granta Park.
(18:40):
So literally a stone's throw fromwhere I'm sat talking to you today.
And I was recruited there as apharmacologist and I was there for six
years in small molecule drug discovery.
Leading a team of pharmacologists as well.
And then 2008 came, and you so sorry.
(19:00):
I should say in that six year period,Celltech were acquired by a Belgian,
medium sized pharma company called UCB.
So that for me at that time wasso quite junior in an industry
career, was you felt that the rughad been taken from under you.
We've been acquired.
What are they gonna do?
(19:21):
They're headquartered in Belgium.
Are they gonna shut us down?
That's your first veryhuman, visceral thought.
No they didn't and we keep doingwhat you are doing otherwise
you play to that narrative thatsort of negative human thinking.
And so yeah, I think that was about2005 that, that deal all went through.
But then in 2008 they didannounce the closure of that
(19:44):
Cambridge, the Granta Park site.
They kept the Slough siteand that's still going today.
And I was one of the few lucky ones.
At the time that was offeredretention within UCB, but it meant
relocation to Slough and I thoughtI'll see what else is out there.
It was a fantastic plan B and a plan Bthat many of my colleagues didn't have.
So I was acutely aware of that.
(20:06):
But then through friends, people in yournetwork fighting the corner, going, I
think this job could be good for you.
I joined Janssen, which at the,that was the name at the time, the
pharmaceutical arm of Johnson and Johnson.
They've now rebranded to Johnsonand Johnson Innovative Medicine,
(20:27):
but then they were Janssen.
But I moved away from the bench, soI stopped being a bench scientist
conducting the experiments.
I moved to launch a product.
Yeah, so I was the product and therapyarea expert for a drug called Stelara,
which I still feel that I, I'mStelara to the core, the molecule, the
(20:49):
mechanism, but not just that it was,so that's the scientist in me talking,
but it was, I was getting closer tothe dermatologist prescribing that.
Sarah McLusky (20:59):
So what's a drug for?
Louise Jopling (21:01):
So it was launched as the first indication in psoriasis,
Sarah McLusky (21:04):
right?
Okay.
Yeah.
Louise Jopling (21:05):
And it was a different mechanism of action, a new, totally
new mechanism of action to theother biologic therapies that had
been on the market for psoriasis.
It's now got indications acrossa number of different diseases,
psoriatic arthritis and inflammatorybowel disease, for example.
But, that was the impact that youcould, you knew about or you could
(21:30):
see for the patients, the quality oflife and that permeating not just for
that patient and what it meant forthem, but for their family members
or their social lives and just, thoseare the, I still get goosebumps now
just even talking to you about it.
I was, I had the pleasure to attenda psoriasis clinic in Manchester.
(21:53):
At what was Salford Royal at the time,and just hearing those individual patient.
Stories, their journeys with thischronic debilitating disease.
They'll stay with me forever.
But it just yeah, itwas just awe inspiring.
But I think one of the otherpieces that, that role taught me.
(22:16):
So I was covering the whole of the UK.
Yeah.
So I was engaging withdermatology departments.
I got to see all parts of the UK.
Some I might not necessarilywanna go back to, but you know
how it just opened your horizons.
But it, you got to really hear thechallenges of the healthcare system, the
prescribers at the time, the nurses, andwhat, whatever those challenges were, but
(22:42):
helping them understand the appropriateplace for use of that particular
drug in amongst all of the others.
How do I make those treatment decisions?
And that drug wasn't necessarily, youwouldn't give it to every patient that
came through your clinic door next.
(23:03):
It was just ah, but it now is an option.
Whereas we didn't have thatoption so many months prior.
But one of the biggest learningsI had was training a sales force.
Mm-hmm.
They didn't care about the immunologyprinciples of how Stelara worked.
They just wanted, what aremy key selling messages?
How can I understand all ofthis complicated science.
(23:23):
And that was just fantastic.
And many of those, I'mstill in touch with today.
So yeah, overall I wasat Janssen for 11 years.
Five of those on that medicalaffairs side of the business.
Very much on the commercial side.
So I moved very quickly from a UK toa, what we call a regional role, right?
(23:44):
Yeah.
That was Europe, Middle East, and Africa.
So that was even more travelthan I'd been doing before.
And then about 2012, 2013 Johnsonand Johnson announced the opening of
their innovation centres globally.
There were four at the time acrossthe globe to really engage with
the external scientific community.
(24:07):
So the biotech companies, theuniversities, the investors in
the EMEA region, for example.
And the office is based in London and.
I felt that was gonna take memuch more back onto the sort
of r and d side of things.
Yeah, the earlier drug discoverythrough to development.
(24:28):
And in essence, Ishoehorned my way in there.
There wasn't a job created, Ihad to find creative ways to
de-risk it for the business.
Because this was a whole newconcept to these innovation centres.
They'd got individuals foreach of the therapy areas.
(24:49):
Immunology was the therapy area Iworked in and wanted to stay in and
had appointed somebody to lead that.
Yeah, I just thought what aboutif I do a secondment for a year,
and if we can create the businesscase for a second headcount role.
Then great.
If not, I'll find something else.
(25:11):
And within nine months we'dcreated the headcount role.
And built a portfolio that was fromreally early, exploratory blue sky
science through to clinical proof ofconcept molecules that ran external
to what we were doing internally.
'cause that was the whole point.
You didn't want it to competewith internal resources.
(25:31):
But yeah, so that wasa real buzz and Yeah.
Yeah, I was, I did that for six years.
And then about that time at thattime I was headhunted for a role
at an organisation that's nowcalled Health Innovation East
to be their commercial director.
I didn't really know what HealthInnovation East did, but in essence
(25:55):
they're funded partly by the NHS andOffice for Life Sciences to bring
health technologies at pace to theirlocal NHS and Health Innovation East.
The east part refers to the East ofEngland, so that's a population of about
(26:15):
five and a half to 6 million people.
I happen to live in the East of England.
Yeah, so due to my family.
So anything that could expeditetheir diagnosis, their treatment
journeys, whatever that was.
That felt really compelling.
So yeah, my, my team, I hadto set up a team from scratch.
And when I left after six years,so that was in October, 2024 I.
(26:40):
The team were about 14 people.
A mixture of industry secondmentsas well as headcount employees
of all sorts of experiences.
And we really were the engineroom working with the companies.
From the small medTech companies tothe very large corporates, the Johnson
(27:02):
Johnsons, the AstraZenecas and everybodyelse, and really helping them develop
their value propositions so that thenwhen we brokered that conversation with
stakeholders within the NHS, it was itwas a much more fulfilling conversation
for everybody's time, rather than,oh, we've been trying to get into that
(27:26):
particular hospital or speak to GPs.
And some of that was small companieshelping them with their product
design and getting it in the handsof who would be eventual users.
And, one company, through a veryearly, what we call the public
patient involvement session.
(27:47):
They claim that they got toproduct design freeze 12 months
earlier than if they hadn't havedone that at that moment in time.
So again, I think as founders or asscientists or maybe clinicians as well,
we focus on what we're trying, whatthe tech, yeah, what all the fancy
stuff is that we're trying to do.
(28:09):
And we don't always think to let'sjust sanity check this with, even
if it's just two or three end users.
That's not quite working orI can't see the result there.
Yeah.
Okay.
Now we need to work on that.
Sarah McLusky (28:23):
Yeah.
Oh.
As somebody who's a huge advocatefor, patient and public involvement.
It's great to hear the difference thatit makes 'cause sometimes when you tell
people and they're a bit like, oh yeah.
Whatever.
But yeah to actually have atangible difference is amazing.
And so it makes sense hearing all aboutyour history there, why you are such a
good candidate for this entrepreneur inresidence role, having this experience
(28:46):
across lots of different organisations,but I can tell from just the way
you're speaking that it's that making adifference in the real world that seems
to be the thing that really motivates you.
Louise Jopling (28:56):
Yeah, absolutely.
And.
Again, just, it is gonna sound a bittrite whenever I say it, but as I said
in my previous role at Health InnovationEast, it was very much the local
news happens to be called Look East.
And there was, an occasionwhere this particular device I
referenced about the user insightsand that was on the teatime news.
Sarah McLusky (29:20):
Oh, fantastic.
Louise Jopling (29:21):
And I was able to put on my family WhatsApp chat.
Oh look, check the news out there.
And just to feel you were alittle crumb in the whole journey.
And that now coming to patients orbeing much more widely known about.
Yeah that's just.
Yeah, I don't need to be the spokespersonor the front person for it, but just, and
(29:44):
also for those founders, it's such a hard,hard and lonely journey for the founders
and for those small companies to really,I'm just blown away by their resilience.
Constantly.
And if I can just help them overcomewhatever that barrier is, and sometimes
it is just having an objectiveshoulder to cry on or ear to li that
(30:10):
listens to and can play stuff back.
Perhaps in a, with other perspectives.
But what's lovely is those founders neverforget and they're so thankful and you
just think it, to me, that now feels atiny little thing given where you've got
to now, how much money you've raised,how many patients you are supporting.
(30:32):
But yeah it's quite humblingin that kind of way.
So yeah that's what gets meoutta bed in the morning.
Sarah McLusky (30:39):
Yeah.
It's really coming across.
And so I do like to ask all of myguests this question, but if you had
a magic wand, what would you changeabout the world that you work in?
Louise Jopling (30:50):
Oh, equitable access.
For every patient or person, that neededa particular health technology, let's
call it, not necessarily a drug, buthealth technology, equitable access.
We don't have equitable access in theUK or in England, let alone globally.
(31:13):
So that's what it would be.
Sarah McLusky (31:14):
Yeah.
So is this meaning what they talk aboutas the postcode lottery side of things?
Yeah.
Yeah.
Louise Jopling (31:20):
Yeah, definitely.
Sarah McLusky (31:21):
No, that does sound, and when you hear about all these
new technologies and treatments andthings that are coming out, it, I
guess is I probably not the onlyperson who goes through your mind.
You're like, oh yeah, that'swell and good, but will
anybody actually get to use it?
Yeah.
Yes.
That would indeed be a fantastic thing.
Keeping an eye on the time.
We should probably think aboutwrapping up our conversation.
(31:43):
So if anybody wants to find outmore about you or the work that
they, that you do, whereaboutswould be the best place to find out?
Louise Jopling (31:50):
So I've got LinkedIn profile so anybody can message me on that.
And then we can connect through,through emails and things thereafter.
Finding out about what the BabrahamResearch Campus does we've got a website
and on that we've got our impact report,which is a nice distilled summary of
the, basically the economic impacts,job creation and investment raised
(32:15):
by the companies that we support.
But it's got everything elsethat we do on the campus as well.
Sarah McLusky (32:21):
Oh, that sounds fantastic.
We'll get links for both of thoseand put them in the show notes.
It just remains to say thank youso much for taking the time to
come along and share what you doand your journey to get there.
It has been really interesting.
Louise Jopling (32:33):
Oh, thank you very much, Sarah.
Likewise.
Sarah McLusky (32:36):
Thanks for listening to Research Adjacent.
If you're listening in a podcast app,please check your subscribed and then
use the links in the episode descriptionto find full show notes and to follow
the podcast on LinkedIn or Instagram.
You can also find all the links andother episodes@www.researchadjacent.com.
Research Adjacent is presentedand produced by Sarah McLusky,
(32:57):
and the theme music is byLemon Music Studios on Pixabay.
And you, yes you, get a big goldstar for listening right to the end.
See you next time.
Now you can make your career sound as, oh, it was
all planned out when I was 15and this is the path I went on.
We know that's all gonnabe generally hogwash.
The impact that you knew about oryou could see for the patients, the
quality of life and that permeating notjust for that patient, but for their
(00:22):
family members or their social lives.
I still get goosebumps now justeven talking to you about it.
It's such a hard and lonely journey forthe founders and for those small companies
I'm just blown away by their resilience.
Sarah McLusky (00:41):
Hello there.
I'm Sarah McLusky andthis is Research Adjacent.
Each episode I talk to amazing researchadjacent professionals about what
they do and why it makes a difference.
Keep listening to find out why wethink the research adjacent space
is where the real magic happens.
(01:05):
Hello and welcome to theResearch Adjacent podcast.
I'm your host, Sarah McLusky, andtoday we'll be meeting Louise Jopling.
Louise is currently the ChiefScientific and Innovation Officer
at the Babraham Research Campus, abiotech business park in Cambridge.
She's also entrepreneur in residenceat the academic Babraham Institute,
which is on the same site.
Louise originally aspired to be a vet,but became an immunologist instead.
(01:29):
She started out on an academic researchpath, but ultimately moved into the
commercial side of the biotech industry,a career move which included launching the
psoriasis drug Stelara and commercialisingother healthcare innovations.
Now she supports both fledging andestablished businesses, as well as
helping academic researchers explore thepotential applications of their work.
(01:49):
In our conversation, we talk about whythe Babraham Research Campus is such a
special place, her career story and whymaking a difference to real people is
what gets her out of bed in the morning.
Listen on to hear Lou's story.
Welcome Lou along to theResearch Adjacent podcast.
It's fantastic to have you here.
(02:10):
I wonder if we could begin byjust hearing a little bit about
who you are and what you do.
Louise Jopling (02:16):
Great.
Thanks Sarah, and lovely to meet you.
So yes, Louise Jopling.
My day job is as Chief Scientific andInnovation Officer at the Babraham
Research Campus in Cambridge.
I'm also a Royal Society entrepreneurin residence at the Babraham Institute.
My day job as CSIO is very much aroundworking with the 60 life sciences
(02:45):
companies that we have on campus, andthey are anything from a two person
startup through to a hundred, 150person grow on scale up company that
have grown while speaking on campus,perhaps over the past decade or more.
And it's understandingwhat their needs are.
Helping, especially the small companiescome out of stealth mode, develop
(03:07):
their data package so that they becomeready to put in front of investors.
Making those connectionsbetween researchers, clinical
teams as well and investors.
Investors in particular because ofthe financial markets that we're
in, particularly in life sciences.
Sarah McLusky (03:26):
So yeah, at the Babraham Research campus, then
it's a site so near Cambridge.
Louise Jopling (03:31):
Yes, that's right.
Yeah.
About six miles south of Cambridge.
So yeah, we are in, inthe southern cluster.
If you know where AddenbrookesHospital is and if you know where
the Wellcome Genome Campus is, thenwe're right slap bang in the middle.
Okay.
Yeah.
You're driving past us,so pop in and say hi.
Sarah McLusky (03:48):
Yeah.
And so it's all focused on lifesciences then all the research
that goes on on that site.
Could you give us maybe a coupleof examples of the sorts of things
that people are doing there?
Louise Jopling (03:59):
Oh yeah.
So we've got companies that aresupporting other companies in their
development, their drug discovery andtheir drug development capabilities.
So often small companies don'thave those skill sets in-house.
Maybe haven't got quite theindustry training in generating
(04:22):
those robust data packages.
So not quite acting as a CRO, but orcontract research organisation, but
actually working in true partnership toenable them to develop that data package
for toxicology, for their formulationof their drug or their molecule.
So that's a sort of very high levelexample for one of the companies.
(04:45):
And then we've got some very early earlystage startup companies, very much around
antibody and biologics engineering.
Sarah McLusky (04:54):
Yeah.
Louise Jopling (04:55):
So as a campus, monoclonal antibodies are our sweet spot these days.
Quite a lot of those proteinmodalities are very much around
the antibody drug conjugates.
It's a lot about AI or machinelearning, helping inform the best
target to go after or targets.
And the best combinations, let'ssay, of whether it's two, two drugs
(05:18):
in combination or whether it's aparticular conjugate once that molecule
has gotten onto or inside the cell.
Yeah, the, and the research focusof the Institute is very much around
we, if we say healthy aging, thatsort of makes us tend to think about
the later stages of the life course.
But actually the research focusesacross all life stages for human health.
(05:42):
So from birth to death.
And it's really about we allknow we are living longer, but
we're not healthier for longer.
Yeah.
We all still have an average of aboutthe last 20 years is in poor health,
and that's where the health healthcareorganisation really is needed.
So it's aiming for thatlifespan to be extended.
Sarah McLusky (06:04):
Oh, fantastic.
And I imagine having all of thosecompanies and that intense research
all happening in the same placeis fantastic for support and
collaboration and those sorts of things.
And it, it sounds like that'svery much part of your role.
Louise Jopling (06:17):
Absolutely.
Yeah.
We've got the academic researchersand the companies on campus,
companies off campus as well.
Theoretically on, even within theperimeter of our campus, and we
are on 430 acres, I should say.
We don't use that by any stretch.
And, again, you could imagine justeven getting between buildings, but,
(06:40):
just to have that close proximity.
And we've got a central sort ofbuilding where people from all
across the campus come for theirlunch, their coffees, their meetings.
So it creates, I call it the meltingpot 'cause that's really where
those serendipitous interactionscould and should be happening.
Mm-hmm.
And part of what I want to bring aswell is how can we really maximize that?
(07:03):
So you're not always,you need a critical mass.
You need to be coming to where everybodyis, but can we enable that at other parts
of the campus as well and in other ways?
Yeah.
But I think through the funding that,that we get through the BBSRC, which
is the Biotechnology and BiologicalSciences Research Council that
(07:25):
really does it pump primes thoseacademic industry partnerships.
And there's also a collaborative PhDstudentship programmme on campus that
has supported or is supporting 22 PhDstudents all at different stages of their
journey where they have to spend at leastthree months in their industrial company.
(07:50):
Oh yeah.
organisation.
Now, whether that's three months asa single time period, or whether it's
a week here, a week there, but theyget that industry supervisor as well.
So Really, yeah.
Really great opportunities.
Sarah McLusky (08:04):
Really fantastic.
Yes.
To connect up that research withthat real world potential impact.
Yeah.
Which is such a big aim now for research.
So how does all of this dovetailwith the entrepreneur in residence
role that you have as well?
Louise Jopling (08:19):
Yeah, I'd say dovetails seamlessly.
Yeah.
But obviously I would say that.
So the entrepreneur in residencerole, so that is specifically
for the academic Institute.
And it is to support the translationand centres of the research
conducted within the Institute.
(08:39):
Now it's a smallinstitute about 350 staff.
So you know, mostly scientists from PhDstudent up through to group leaders.
But there's also someheads of core facilities.
So these are real capability centresof excellence, if you like that
(09:00):
are funded by BBSRC, particularlyto serve the academic research.
But where bandwidth exists withinthose core facilities and what
I mean by those core facilities,it might be a flow cytometry.
It might be cell it might be sequencing,might be an animal unit as well 'cause
often some analysis needs to be conductedin in vivo. So they're just some examples.
(09:27):
But where there's bandwidth withinthose facilities, then the companies
themselves that are on campus canactually pay to to use those services
and to enable their discoveries and onevery small company, they're in stealth
currently, so I can't say their name.
Yeah.
But did describe being on campus ashaving your own CRO contract research
(09:51):
organisation on your doorstep.
So he, the CEO and founder wasparticularly, he was walking over
to our central stores facility.
Doesn't sound very exciting, butactually it's this massive procurement
hub, off the scale, that enables thescience for the companies and for
(10:15):
the institute to happen seamlessly.
They're not have, the small company isnot having to negotiate with 500 different
suppliers for basic things like glovesthrough to high, highly complex stuff.
They can just move in, move onto campus, crack on with their
science and everything else is.
(10:35):
Is, taken care of.
But going back to the institute itself,obviously it conducts many more enabling
services in addition to the research,but yeah, the world leading research,
high impact papers from the groupleaders, the PhD students, and everybody
(10:57):
in between, and all enabled by thatinfrastructure and the capabilities.
So yeah, it, as I say, it's asmall institute relative to, quite
large universities, et cetera.
But that's meant I've been reallyable to get under the bonnet of all
of the science that's going on hereand all of those centres projects.
(11:19):
And I think one of my biggest challengesor things that I wrestled with at
the start of the fellowship was howcan I make an impact one day a week?
Parachuting into the institute andand it was really getting under the
bonnet of all of the programmmesthat were in the commercialisation
(11:39):
portfolio, let's call it, and workingout, these are the ones that are
perhaps more, more mature or that,that really, I could bring an impact.
So there's about four or five that I'mreally actively working on it doesn't
mean I'm ignoring the others, but it just,they're not all equal at the same moment.
Sarah McLusky (11:59):
Yeah.
And also as you say, one day a week, youcan only do a limited amount of stuff.
So you have to prioritizeto a certain extent.
Yeah.
Louise Jopling (12:09):
I think, yeah, I think it's like when you start any
new job you think of your, what'syour 30, 60, 90 day plan or the
first a hundred days gonna look like.
And I very quickly realized,actually my first 30 days is
really only going to be four days.
So that was a real awakening.
And, not a bad thing, but it just, meansthat, yeah, you do focus and prioritize,
(12:32):
but I think the other piece that.
It's not just about the science andtranslating that is a core piece, but it
is also about and this is the nature ofthis podcast, research adjacent, and it
is about helping hone and inspire sortof the scientists from wherever they
(12:55):
are in their career journey, in theirown research and their own aspirations.
And I got to present a Science360 talk, which was very much
talk us through your career.
Now you can make your career soundas, oh, it was all planned out when I
was 15 and this is the path I went on.
(13:15):
We know that's all gonnabe generally hogwash.
Sarah McLusky (13:18):
Yeah.
Louise Jopling (13:18):
For, majority of us.
And just talking that through andactually bringing that to life.
And it wasn't just attended bythe more junior or people at the
earlier stages of their career.
There were some really quite seniorindividuals in that audience asking
particular questions pertinent to their,where they were at that moment in time,
(13:41):
whether that was from a professional,but also from a personal perspective.
And a lot of it is howdoes one manage one's time.
None of, I think if anybody hadgot that nailed, we'd have patented
it and be making yeah, money out.
Sarah McLusky (13:55):
Yeah somebody would be making a lot of money out it,
Louise Jopling (13:57):
B ut I think sometimes one can project things as if, yeah,
it's all sorted and it's all a doddleand that's how it can look to others.
But actually really getting underthe skin of either what drives me or
what, where you might have had to makepersonal sacrifices or compromises.
(14:18):
Yeah.
It's, it just shows that authenticityand the fact that you're human.
Sarah McLusky (14:23):
Yeah.
And I think that's leading us reallynicely then to just invite you to tell
us a bit about your career journey,about how you've ended up where you are
now, what kind of jobs you've done alongthe way what, what's your path been?
Louise Jopling (14:37):
Yeah.
So overall so I'm a scientist by training.
I always wanted to be a vet. So fromwhen I was about 11, when unfortunately
my cat needed to be put down.
I, he was my cat and I felt if Iwas the vet, I'd have saved him.
Of course what an arrogant 11-year-old,of course you're gonna think that.
(14:57):
However, followed that and focusedup purely on science throughout
GCSEs A levels and university.
I didn't get into veterinary atthe time, but I'd got my my other
courses I'd applied for animalbiology, so zoology, but I wanted
to specialise in parasitology.
So worms, parasites.
(15:19):
Yeah.
Which led me to studyup in Scotland actually.
And it was based on where the course was.
I was always fascinated by howparasites evade the host immune system.
Sarah McLusky (15:30):
Yeah.
Louise Jopling (15:30):
Again, that then led me onto my immunology research path.
So I describe, I'm nolonger a parasitologist.
I still remember all of those things.
But as a, as an immunologist, Igot a very great grounding in my
first two roles after I graduated.
And I should just say after I graduatedfrom the University of Aberdeen, I
(15:55):
did an eight week summer studentshipactually at the Babraham Institute.
And I didn't realize quite howcircular this was all going to be.
So again, I could make that be a perfectstory, but it's not meant that way anyway.
I did a couple of research assistantposts to get experience in the lab.
One of which, at the University ofEdinburgh at the Center for HIV research.
(16:19):
And at that time, so that was the midnineties when chemokine receptors,
these G protein coupled receptorshad been identified as co-receptors
for viral entry into cells.
They were facilitating the HIV virus,getting into cells and then amplifying.
And that was a really sweettime in as much as it really
(16:43):
captured my scientific interest.
And it was, we were on the startof that crest of the wave around
that particular area of research.
And so really I followed that familyof receptors throughout probably
the next decade plus of my career.
And that was in bothacademia but also in biotech.
(17:04):
So I did my two research assistantposts, got experience in the lab,
competent, and I then applied to what wasEurope's leading chemokine receptor lab.
And just the letter I wrote I read itback some years ago and it was quite
cringe, but my timing was fantastic.
(17:25):
It was all I one, the chemokine receptorswere wonderful, this, that, and the other.
My research and that I, butI really wanted to do PhD.
Fortunately that lab at the timebased at Imperial College had a,
had attracted some industry funding.
So in essence I was industry funded.
It was a US biotech company.
And so for three years I conductedmy PhD research and I think what
(17:48):
was great was I was able to conductthat research within three years.
So from registration to submission,
Sarah McLusky (17:55):
That is impressive.
Louise Jopling (17:57):
Yeah, no, thank you.
But I think it was because I'dalready earned my stripes and got
my lab skills in the two years priorin those research assistant posts.
So again, that, that really enabled that.
Anyway, I then followed the receptorI'd been working on in my PhD out
to Boston to Harvard Med School.
So I was working at Children'sHospital and that was fantastic.
(18:19):
So then in 2000, end of2002, I came back to the UK.
I always thought I was gonnastay in academia to be quite
honest, but never say never.
And I came back to a job in biotech.
Yeah.
And at the time it was Britain'sbiggest biotech company called Celltech.
And Celltech had a small moleculesite in Cambridge on Granta Park.
(18:40):
So literally a stone's throw fromwhere I'm sat talking to you today.
And I was recruited there as apharmacologist and I was there for six
years in small molecule drug discovery.
Leading a team of pharmacologists as well.
And then 2008 came, and you so sorry.
(19:00):
I should say in that six year period,Celltech were acquired by a Belgian,
medium sized pharma company called UCB.
So that for me at that time wasso quite junior in an industry
career, was you felt that the rughad been taken from under you.
We've been acquired.
What are they gonna do?
(19:21):
They're headquartered in Belgium.
Are they gonna shut us down?
That's your first veryhuman, visceral thought.
No they didn't and we keep doingwhat you are doing otherwise
you play to that narrative thatsort of negative human thinking.
And so yeah, I think that was about2005 that, that deal all went through.
But then in 2008 they didannounce the closure of that
(19:44):
Cambridge, the Granta Park site.
They kept the Slough siteand that's still going today.
And I was one of the few lucky ones.
At the time that was offeredretention within UCB, but it meant
relocation to Slough and I thoughtI'll see what else is out there.
It was a fantastic plan B and a plan Bthat many of my colleagues didn't have.
So I was acutely aware of that.
(20:06):
But then through friends, people in yournetwork fighting the corner, going, I
think this job could be good for you.
I joined Janssen, which at the,that was the name at the time, the
pharmaceutical arm of Johnson and Johnson.
They've now rebranded to Johnsonand Johnson Innovative Medicine,
(20:27):
but then they were Janssen.
But I moved away from the bench, soI stopped being a bench scientist
conducting the experiments.
I moved to launch a product.
Yeah, so I was the product and therapyarea expert for a drug called Stelara,
which I still feel that I, I'mStelara to the core, the molecule, the
(20:49):
mechanism, but not just that it was,so that's the scientist in me talking,
but it was, I was getting closer tothe dermatologist prescribing that.
Sarah McLusky (20:59):
So what's a drug for?
Louise Jopling (21:01):
So it was launched as the first indication in psoriasis,
Sarah McLusky (21:04):
right?
Okay.
Yeah.
Louise Jopling (21:05):
And it was a different mechanism of action, a new, totally
new mechanism of action to theother biologic therapies that had
been on the market for psoriasis.
It's now got indications acrossa number of different diseases,
psoriatic arthritis and inflammatorybowel disease, for example.
But, that was the impact that youcould, you knew about or you could
(21:30):
see for the patients, the quality oflife and that permeating not just for
that patient and what it meant forthem, but for their family members
or their social lives and just, thoseare the, I still get goosebumps now
just even talking to you about it.
I was, I had the pleasure to attenda psoriasis clinic in Manchester.
(21:53):
At what was Salford Royal at the time,and just hearing those individual patient.
Stories, their journeys with thischronic debilitating disease.
They'll stay with me forever.
But it just yeah, itwas just awe inspiring.
But I think one of the otherpieces that, that role taught me.
(22:16):
So I was covering the whole of the UK.
Yeah.
So I was engaging withdermatology departments.
I got to see all parts of the UK.
Some I might not necessarilywanna go back to, but you know
how it just opened your horizons.
But it, you got to really hear thechallenges of the healthcare system, the
prescribers at the time, the nurses, andwhat, whatever those challenges were, but
(22:42):
helping them understand the appropriateplace for use of that particular
drug in amongst all of the others.
How do I make those treatment decisions?
And that drug wasn't necessarily, youwouldn't give it to every patient that
came through your clinic door next.
(23:03):
It was just ah, but it now is an option.
Whereas we didn't have thatoption so many months prior.
But one of the biggest learningsI had was training a sales force.
Mm-hmm.
They didn't care about the immunologyprinciples of how Stelara worked.
They just wanted, what aremy key selling messages?
How can I understand all ofthis complicated science.
(23:23):
And that was just fantastic.
And many of those, I'mstill in touch with today.
So yeah, overall I wasat Janssen for 11 years.
Five of those on that medicalaffairs side of the business.
Very much on the commercial side.
So I moved very quickly from a UK toa, what we call a regional role, right?
(23:44):
Yeah.
That was Europe, Middle East, and Africa.
So that was even more travelthan I'd been doing before.
And then about 2012, 2013 Johnsonand Johnson announced the opening of
their innovation centres globally.
There were four at the time acrossthe globe to really engage with
the external scientific community.
(24:07):
So the biotech companies, theuniversities, the investors in
the EMEA region, for example.
And the office is based in London and.
I felt that was gonna take memuch more back onto the sort
of r and d side of things.
Yeah, the earlier drug discoverythrough to development.
(24:28):
And in essence, Ishoehorned my way in there.
There wasn't a job created, Ihad to find creative ways to
de-risk it for the business.
Because this was a whole newconcept to these innovation centres.
They'd got individuals foreach of the therapy areas.
(24:49):
Immunology was the therapy area Iworked in and wanted to stay in and
had appointed somebody to lead that.
Yeah, I just thought what aboutif I do a secondment for a year,
and if we can create the businesscase for a second headcount role.
Then great.
If not, I'll find something else.
(25:11):
And within nine months we'dcreated the headcount role.
And built a portfolio that was fromreally early, exploratory blue sky
science through to clinical proof ofconcept molecules that ran external
to what we were doing internally.
'cause that was the whole point.
You didn't want it to competewith internal resources.
(25:31):
But yeah, so that wasa real buzz and Yeah.
Yeah, I was, I did that for six years.
And then about that time at thattime I was headhunted for a role
at an organisation that's nowcalled Health Innovation East
to be their commercial director.
I didn't really know what HealthInnovation East did, but in essence
(25:55):
they're funded partly by the NHS andOffice for Life Sciences to bring
health technologies at pace to theirlocal NHS and Health Innovation East.
The east part refers to the East ofEngland, so that's a population of about
(26:15):
five and a half to 6 million people.
I happen to live in the East of England.
Yeah, so due to my family.
So anything that could expeditetheir diagnosis, their treatment
journeys, whatever that was.
That felt really compelling.
So yeah, my, my team, I hadto set up a team from scratch.
And when I left after six years,so that was in October, 2024 I.
(26:40):
The team were about 14 people.
A mixture of industry secondmentsas well as headcount employees
of all sorts of experiences.
And we really were the engineroom working with the companies.
From the small medTech companies tothe very large corporates, the Johnson
(27:02):
Johnsons, the AstraZenecas and everybodyelse, and really helping them develop
their value propositions so that thenwhen we brokered that conversation with
stakeholders within the NHS, it was itwas a much more fulfilling conversation
for everybody's time, rather than,oh, we've been trying to get into that
(27:26):
particular hospital or speak to GPs.
And some of that was small companieshelping them with their product
design and getting it in the handsof who would be eventual users.
And, one company, through a veryearly, what we call the public
patient involvement session.
(27:47):
They claim that they got toproduct design freeze 12 months
earlier than if they hadn't havedone that at that moment in time.
So again, I think as founders or asscientists or maybe clinicians as well,
we focus on what we're trying, whatthe tech, yeah, what all the fancy
stuff is that we're trying to do.
(28:09):
And we don't always think to let'sjust sanity check this with, even
if it's just two or three end users.
That's not quite working orI can't see the result there.
Yeah.
Okay.
Now we need to work on that.
Sarah McLusky (28:23):
Yeah.
Oh.
As somebody who's a huge advocatefor, patient and public involvement.
It's great to hear the difference thatit makes 'cause sometimes when you tell
people and they're a bit like, oh yeah.
Whatever.
But yeah to actually have atangible difference is amazing.
And so it makes sense hearing all aboutyour history there, why you are such a
good candidate for this entrepreneur inresidence role, having this experience
(28:46):
across lots of different organisations,but I can tell from just the way
you're speaking that it's that making adifference in the real world that seems
to be the thing that really motivates you.
Louise Jopling (28:56):
Yeah, absolutely.
And.
Again, just, it is gonna sound a bittrite whenever I say it, but as I said
in my previous role at Health InnovationEast, it was very much the local
news happens to be called Look East.
And there was, an occasionwhere this particular device I
referenced about the user insightsand that was on the teatime news.
Sarah McLusky (29:20):
Oh, fantastic.
Louise Jopling (29:21):
And I was able to put on my family WhatsApp chat.
Oh look, check the news out there.
And just to feel you were alittle crumb in the whole journey.
And that now coming to patients orbeing much more widely known about.
Yeah that's just.
Yeah, I don't need to be the spokespersonor the front person for it, but just, and
(29:44):
also for those founders, it's such a hard,hard and lonely journey for the founders
and for those small companies to really,I'm just blown away by their resilience.
Constantly.
And if I can just help them overcomewhatever that barrier is, and sometimes
it is just having an objectiveshoulder to cry on or ear to li that
(30:10):
listens to and can play stuff back.
Perhaps in a, with other perspectives.
But what's lovely is those founders neverforget and they're so thankful and you
just think it, to me, that now feels atiny little thing given where you've got
to now, how much money you've raised,how many patients you are supporting.
(30:32):
But yeah it's quite humblingin that kind of way.
So yeah that's what gets meoutta bed in the morning.
Sarah McLusky (30:39):
Yeah.
It's really coming across.
And so I do like to ask all of myguests this question, but if you had
a magic wand, what would you changeabout the world that you work in?
Louise Jopling (30:50):
Oh, equitable access.
For every patient or person, that neededa particular health technology, let's
call it, not necessarily a drug, buthealth technology, equitable access.
We don't have equitable access in theUK or in England, let alone globally.
(31:13):
So that's what it would be.
Sarah McLusky (31:14):
Yeah.
So is this meaning what they talk aboutas the postcode lottery side of things?
Yeah.
Yeah.
Louise Jopling (31:20):
Yeah, definitely.
Sarah McLusky (31:21):
No, that does sound, and when you hear about all these
new technologies and treatments andthings that are coming out, it, I
guess is I probably not the onlyperson who goes through your mind.
You're like, oh yeah, that'swell and good, but will
anybody actually get to use it?
Yeah.
Yes.
That would indeed be a fantastic thing.
Keeping an eye on the time.
We should probably think aboutwrapping up our conversation.
(31:43):
So if anybody wants to find outmore about you or the work that
they, that you do, whereaboutswould be the best place to find out?
Louise Jopling (31:50):
So I've got LinkedIn profile so anybody can message me on that.
And then we can connect through,through emails and things thereafter.
Finding out about what the BabrahamResearch Campus does we've got a website
and on that we've got our impact report,which is a nice distilled summary of
the, basically the economic impacts,job creation and investment raised
(32:15):
by the companies that we support.
But it's got everything elsethat we do on the campus as well.
Sarah McLusky (32:21):
Oh, that sounds fantastic.
We'll get links for both of thoseand put them in the show notes.
It just remains to say thank youso much for taking the time to
come along and share what you doand your journey to get there.
It has been really interesting.
Louise Jopling (32:33):
Oh, thank you very much, Sarah.
Likewise.
Sarah McLusky (32:36):
Thanks for listening to Research Adjacent.
If you're listening in a podcast app,please check your subscribed and then
use the links in the episode descriptionto find full show notes and to follow
the podcast on LinkedIn or Instagram.
You can also find all the links andother episodes@www.researchadjacent.com.
Research Adjacent is presentedand produced by Sarah McLusky,
(32:57):
and the theme music is byLemon Music Studios on Pixabay.
And you, yes you, get a big goldstar for listening right to the end.
See you next time.
Popular Podcasts
NFL Daily with Gregg Rosenthal
Gregg Rosenthal and a rotating crew of elite NFL Media co-hosts, including Patrick Claybon, Colleen Wolfe, Steve Wyche, Nick Shook and Jourdan Rodrigue of The Athletic get you caught up daily on all the NFL news and analysis you need to be smarter and funnier than your friends.
On Purpose with Jay Shetty
I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com